My watch list
my.bionity.com  
Login  

Recipharm completes strategic acquisition in India

22-Feb-2017

Recipharm AB announces that it has now concluded the acquisition of Kemwell’s pharmaceutical businesses located in Bengaluru, India.

The expands position in emerging markets significantly, taking sales in these markets to more than SEK 800 million, dominated by sales directly to the fast-growing pharma market in India. The acquisition further strengthens Recipharm’s synergistic business model by aligning Indian development and technology operations with the combined Company’s manufacturing capabilities in India and Europe. In addition, there are potential commercial synergies from enhanced customer offering and cross selling.

Thomas Eldered, CEO of Recipharm AB said “I am pleased we have now finally completed this important acquisition. We are now in a position to offer our customers access to cost effective development and manufacturing capabilities able to serve international markets including the US. These acquisitions are already showing great promise and I am pleased the current Managing Director, Anurag Bagaria, and VP Corporate Development, Karan Bagaria, will continue in their current positions going forward.”

Information on the acquired businesses

The acquired business now known as Recipharm Pharmaservices Private Ltd, was originally founded by Subhash Bagaria. It employs around 1 200 people and comprises both development services as well as commercial manufacturing of solid, semi-solid, liquid and topical products, with customer relations spanning decades. The solid dosage plant was commissioned in 2008 and has approvals from US FDA and EU amongst many other regulatory bodies. The oral liquids production plant was commissioned in 2011 and is specialized in automated high throughput large volume manufacturing, mainly for the Indian subcontinent. The development business is a rapidly growing business with a comprehensive service offering including formulation development, small scale manufacturing for clinical trials and a large analytical services business.

Facts, background information, dossiers
  • Recipharm
  • acquisitions
More about Recipharm
  • News

    Recipharm releases first serialised products to Europe

    Recipharm has released its first serialised products to Europe from its facilities in Lisbon, Portugal and Stockholm, Sweden. In 2016 Recipharm committed to invest 40 million euros in preparing its facilities for the European Falsified Medicines Directive (EU FMD). The release of its first ... more

    Sanofi and Recipharm announce transfer of Holmes Chapel Manufacturing site

    Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm. “Holmes Chapel brings Recipharm an ideal opportunity to ... more

    Recipharm invests in Brexit preparations

    Recipharm has established a dedicated taskforce to manage the potential impact of Brexit on its organisation. With less than a year until the UK exits the European Union (EU), the Sweden headquartered global CDMO is focused on managing the transition with minimal impact to its operations an ... more

  • Companies

    Recipharm AB

    Recipharm is a leading contract development and manufacturing organisation based in Europe. The Company operates nine main manufacturing facilities in Sweden, France, the UK and Switzerland and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with in exc ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE